MedTrace Logo

Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

NCT01202253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2014-04-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.

Conditions

  • Candidiasis

Interventions

DRUG

anidulafungin

A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202253 on ClinicalTrials.gov